Defining Synchronous Oligometastatic Non–Small Cell Lung Cancer: A Systematic Review

Niccolò Giaj-Levra; Matteo Giaj-Levra; EORTC Lung Cancer Group (EORTC LCG); Valerie Durieux; Silvia Novello; Benjamin Besse; Baktiar Hasan; Lizza E. Hendriks; Antonin Levy; Anne Marie C. Dingemans; Thierry Berghmans

doi:10.1016/j.jtho.2019.05.037

Defining Synchronous Oligometastatic Non–Small Cell Lung Cancer: A Systematic Review

Niccolò Giaj-Levra
, Matteo Giaj-Levra^*
, EORTC Lung Cancer Group (EORTC LCG)
, Valerie Durieux
, Silvia Novello
, Benjamin Besse
, Baktiar Hasan
, Lizza E. Hendriks
, Antonin Levy
, Anne Marie C. Dingemans
, Thierry Berghmans

^*Corresponding author for this work

Research output: Contribution to journal › Review article › Academic › peer-review

68 Citations (Scopus)

Abstract

Introduction:

Synchronous oligometastatic (sOM) disease is an oncological concept characterized by a limited cancer burden. Patients with oligometastasis could potentially benefit from local radical treatments. Despite the fact that the sOM condition is well recognized, a universal definition, including a specific definition for NSCLC, is not yet available. The aim of this systematic review was to summarize the definitions of and staging requirements for use of the term synchronous oligometastatic in the context of NSCLC.

Methods:

The key issue was formulated in one research question according to the population, intervention, comparator, and outcomes strategy. The question was introduced in MEDLINE (OvidSP). All articles dealing with sOM NSCLC and providing a definition of synchronous oligometastasis in NSCLC were selected and analyzed.

Results:

A total of 21 eligible articles focusing on sOM NSCLC were retrieved and analyzed. In 17 studies (81%), patients had to be staged with magnetic resonance imaging or computed tomography of the brain, thoracic and abdominal computed tomography, and positron emission tomography. The total number of metastases allowed in the definitions ranged from one to eight, but in 38.1% of studies the maximum number was 5. Most of the publications did not define the number of involved organs or the maximum number of metastases per organ. For mediastinal lymph node involvement, only five articles (27.8%) counted this as a metastatic site.

Conclusions:

No uniform definition of sOM NSCLC could be retrieved by this systematic review. However, extended staging was mandated in most of the studies. An accepted oncological definition of synchronous oligometastasis is essential for patient selection to define prospective clinical trials.

Original language	English
Pages (from-to)	2053-2061
Number of pages	9
Journal	Journal of Thoracic Oncology
Volume	14
Issue number	12
DOIs	https://doi.org/10.1016/j.jtho.2019.05.037
Publication status	Published - Dec 2019
Externally published	Yes

Bibliographical note

Funding Information:
This publication was supported by the European Organization for Research and Treatment of Cancer Research Fund.

Funding Information:
Disclosure: Dr. Matteo Giaj-Levra reports personal fees for serving as a speaker for Novartis, Amgen, Bristol-Myers Squibb, AstraZeneca, Roche; and travel grants from Roche, AstraZeneca, and MSD outside the submitted work. Dr. Besse reports institutional grants for clinical and translational research from AbbVie, Amgen, AstraZeneca, Biogen, Blueprint Medicines, BMS, Celgene, Eli Lilly, GSK, Ignyta, IPSEN, Merck KGaA, MSD, Nektar, Onxeo, Pfizer, Pharma Mar, Sanofi, Spectrum Pharmaceuticals, Takeda, and Tiziana Pharma outside the submitted work. Dr. Hendriks from research funding from Roche and Boehringer Ingelheim (both to her institution), personal fees for advisory board service from Boehringer Ingelheim (to her institution) and BMS (both to her institution and to her personally), travel reimbursement to Roche and BMS, participation in a mentorship program with key opinion leaders funded by AstraZeneca, and personal fees for educational webinars from Quadia outside the submitted work. Dr. Dingemans reports fees for advisory board service from Eli Lilly, Roche, Boehringer Ingelheim, Takeda, BMS, and Novartis (all to her institution) outside the submitted work. The remaining authors declare no conflict of interest.This publication was supported by the European Organization for Research and Treatment of Cancer Research Fund.

Publisher Copyright:
© 2019 International Association for the Study of Lung Cancer

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.jtho.2019.05.037

Cite this

@article{83e142732d8f4fddb295fe2c05f6608c,

title = "Defining Synchronous Oligometastatic Non–Small Cell Lung Cancer: A Systematic Review",

abstract = "Introduction: Synchronous oligometastatic (sOM) disease is an oncological concept characterized by a limited cancer burden. Patients with oligometastasis could potentially benefit from local radical treatments. Despite the fact that the sOM condition is well recognized, a universal definition, including a specific definition for NSCLC, is not yet available. The aim of this systematic review was to summarize the definitions of and staging requirements for use of the term synchronous oligometastatic in the context of NSCLC. Methods: The key issue was formulated in one research question according to the population, intervention, comparator, and outcomes strategy. The question was introduced in MEDLINE (OvidSP). All articles dealing with sOM NSCLC and providing a definition of synchronous oligometastasis in NSCLC were selected and analyzed.Results:A total of 21 eligible articles focusing on sOM NSCLC were retrieved and analyzed. In 17 studies (81\%), patients had to be staged with magnetic resonance imaging or computed tomography of the brain, thoracic and abdominal computed tomography, and positron emission tomography. The total number of metastases allowed in the definitions ranged from one to eight, but in 38.1\% of studies the maximum number was 5. Most of the publications did not define the number of involved organs or the maximum number of metastases per organ. For mediastinal lymph node involvement, only five articles (27.8\%) counted this as a metastatic site. Conclusions:No uniform definition of sOM NSCLC could be retrieved by this systematic review. However, extended staging was mandated in most of the studies. An accepted oncological definition of synchronous oligometastasis is essential for patient selection to define prospective clinical trials.",

author = "Niccol{\`o} Giaj-Levra and Matteo Giaj-Levra and \{EORTC Lung Cancer Group (EORTC LCG)\} and Valerie Durieux and Silvia Novello and Benjamin Besse and Baktiar Hasan and Hendriks, \{Lizza E.\} and Antonin Levy and Dingemans, \{Anne Marie C.\} and Thierry Berghmans",

note = "Funding Information: This publication was supported by the European Organization for Research and Treatment of Cancer Research Fund. Funding Information: Disclosure: Dr. Matteo Giaj-Levra reports personal fees for serving as a speaker for Novartis, Amgen, Bristol-Myers Squibb, AstraZeneca, Roche; and travel grants from Roche, AstraZeneca, and MSD outside the submitted work. Dr. Besse reports institutional grants for clinical and translational research from AbbVie, Amgen, AstraZeneca, Biogen, Blueprint Medicines, BMS, Celgene, Eli Lilly, GSK, Ignyta, IPSEN, Merck KGaA, MSD, Nektar, Onxeo, Pfizer, Pharma Mar, Sanofi, Spectrum Pharmaceuticals, Takeda, and Tiziana Pharma outside the submitted work. Dr. Hendriks from research funding from Roche and Boehringer Ingelheim (both to her institution), personal fees for advisory board service from Boehringer Ingelheim (to her institution) and BMS (both to her institution and to her personally), travel reimbursement to Roche and BMS, participation in a mentorship program with key opinion leaders funded by AstraZeneca, and personal fees for educational webinars from Quadia outside the submitted work. Dr. Dingemans reports fees for advisory board service from Eli Lilly, Roche, Boehringer Ingelheim, Takeda, BMS, and Novartis (all to her institution) outside the submitted work. The remaining authors declare no conflict of interest.This publication was supported by the European Organization for Research and Treatment of Cancer Research Fund. Publisher Copyright: {\textcopyright} 2019 International Association for the Study of Lung Cancer",

year = "2019",

month = dec,

doi = "10.1016/j.jtho.2019.05.037",

language = "English",

volume = "14",

pages = "2053--2061",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",

publisher = "Elsevier Inc.",

number = "12",

}

TY - JOUR

T1 - Defining Synchronous Oligometastatic Non–Small Cell Lung Cancer

T2 - A Systematic Review

AU - Giaj-Levra, Niccolò

AU - Giaj-Levra, Matteo

AU - EORTC Lung Cancer Group (EORTC LCG)

AU - Durieux, Valerie

AU - Novello, Silvia

AU - Besse, Benjamin

AU - Hasan, Baktiar

AU - Hendriks, Lizza E.

AU - Levy, Antonin

AU - Dingemans, Anne Marie C.

AU - Berghmans, Thierry

N1 - Funding Information: This publication was supported by the European Organization for Research and Treatment of Cancer Research Fund. Funding Information: Disclosure: Dr. Matteo Giaj-Levra reports personal fees for serving as a speaker for Novartis, Amgen, Bristol-Myers Squibb, AstraZeneca, Roche; and travel grants from Roche, AstraZeneca, and MSD outside the submitted work. Dr. Besse reports institutional grants for clinical and translational research from AbbVie, Amgen, AstraZeneca, Biogen, Blueprint Medicines, BMS, Celgene, Eli Lilly, GSK, Ignyta, IPSEN, Merck KGaA, MSD, Nektar, Onxeo, Pfizer, Pharma Mar, Sanofi, Spectrum Pharmaceuticals, Takeda, and Tiziana Pharma outside the submitted work. Dr. Hendriks from research funding from Roche and Boehringer Ingelheim (both to her institution), personal fees for advisory board service from Boehringer Ingelheim (to her institution) and BMS (both to her institution and to her personally), travel reimbursement to Roche and BMS, participation in a mentorship program with key opinion leaders funded by AstraZeneca, and personal fees for educational webinars from Quadia outside the submitted work. Dr. Dingemans reports fees for advisory board service from Eli Lilly, Roche, Boehringer Ingelheim, Takeda, BMS, and Novartis (all to her institution) outside the submitted work. The remaining authors declare no conflict of interest.This publication was supported by the European Organization for Research and Treatment of Cancer Research Fund. Publisher Copyright: © 2019 International Association for the Study of Lung Cancer

PY - 2019/12

Y1 - 2019/12

N2 - Introduction: Synchronous oligometastatic (sOM) disease is an oncological concept characterized by a limited cancer burden. Patients with oligometastasis could potentially benefit from local radical treatments. Despite the fact that the sOM condition is well recognized, a universal definition, including a specific definition for NSCLC, is not yet available. The aim of this systematic review was to summarize the definitions of and staging requirements for use of the term synchronous oligometastatic in the context of NSCLC. Methods: The key issue was formulated in one research question according to the population, intervention, comparator, and outcomes strategy. The question was introduced in MEDLINE (OvidSP). All articles dealing with sOM NSCLC and providing a definition of synchronous oligometastasis in NSCLC were selected and analyzed.Results:A total of 21 eligible articles focusing on sOM NSCLC were retrieved and analyzed. In 17 studies (81%), patients had to be staged with magnetic resonance imaging or computed tomography of the brain, thoracic and abdominal computed tomography, and positron emission tomography. The total number of metastases allowed in the definitions ranged from one to eight, but in 38.1% of studies the maximum number was 5. Most of the publications did not define the number of involved organs or the maximum number of metastases per organ. For mediastinal lymph node involvement, only five articles (27.8%) counted this as a metastatic site. Conclusions:No uniform definition of sOM NSCLC could be retrieved by this systematic review. However, extended staging was mandated in most of the studies. An accepted oncological definition of synchronous oligometastasis is essential for patient selection to define prospective clinical trials.

AB - Introduction: Synchronous oligometastatic (sOM) disease is an oncological concept characterized by a limited cancer burden. Patients with oligometastasis could potentially benefit from local radical treatments. Despite the fact that the sOM condition is well recognized, a universal definition, including a specific definition for NSCLC, is not yet available. The aim of this systematic review was to summarize the definitions of and staging requirements for use of the term synchronous oligometastatic in the context of NSCLC. Methods: The key issue was formulated in one research question according to the population, intervention, comparator, and outcomes strategy. The question was introduced in MEDLINE (OvidSP). All articles dealing with sOM NSCLC and providing a definition of synchronous oligometastasis in NSCLC were selected and analyzed.Results:A total of 21 eligible articles focusing on sOM NSCLC were retrieved and analyzed. In 17 studies (81%), patients had to be staged with magnetic resonance imaging or computed tomography of the brain, thoracic and abdominal computed tomography, and positron emission tomography. The total number of metastases allowed in the definitions ranged from one to eight, but in 38.1% of studies the maximum number was 5. Most of the publications did not define the number of involved organs or the maximum number of metastases per organ. For mediastinal lymph node involvement, only five articles (27.8%) counted this as a metastatic site. Conclusions:No uniform definition of sOM NSCLC could be retrieved by this systematic review. However, extended staging was mandated in most of the studies. An accepted oncological definition of synchronous oligometastasis is essential for patient selection to define prospective clinical trials.

UR - https://www.scopus.com/pages/publications/85069546715

U2 - 10.1016/j.jtho.2019.05.037

DO - 10.1016/j.jtho.2019.05.037

M3 - Review article

C2 - 31195177

AN - SCOPUS:85069546715

SN - 1556-0864

VL - 14

SP - 2053

EP - 2061

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

IS - 12

ER -

Defining Synchronous Oligometastatic Non–Small Cell Lung Cancer: A Systematic Review

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this